TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges
TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges...…
16,321€
0,59%
Echtzeit-Aktienkurs TG Therapeutics Inc.
Bid:
Ask:
Nachrichten zur TG Therapeutics Inc. Aktie
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do…
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
First quarter 2023 BRIUMVI net sales of $7.8 million...…
TG Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $7.8M beats by $4.42M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K TG THERAPEUTICS, INC. For: May 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
Conference call to be held Monday, May 1, 2023, at 8:30 AM ET Conference call to be held Monday, May…
TG Therapeutics gains after reimbursement win for multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S.…
Why Shares of TG Therapeutics Soared on Tuesday
Early reports of strong sales for its recently approved multiple sclerosis drug gave the stock a jolt....…
TG Therapeutics jumps 22% as Cantor cites strong Briumvi sales
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day....…
TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis >TGTX
TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis >TGTX...…
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal…
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session....…
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day....…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations…
Form 10-K TG THERAPEUTICS, INC. For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do…
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today,…
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February…
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the…
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day....…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations…
TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day....…
TG Therapeutics launches newly approved multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch…
TG Therapeutics nears one-year high
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TG Therapeutics, Inc.
Wilmington, Delaware--(Newsfile Corp. - January 23, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors…
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day....…
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
TG Therapeutics adds 10% to extend gains after insider purchase
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
Insiderhandel: Aufsichtsrat kauft Aktien von TG Therapeutics im Wert von 95.760$
Echelard, Yann - Aufsichtsrat - Tag der Transaktion: 2023-01-06...…
Insiderhandel: Aufsichtsrat verkauft Aktien von TG Therapeutics im Wert von 333.000$
Charney, Laurence N. - Aufsichtsrat - Tag der Transaktion: 2023-01-04...…
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT Presentation scheduled for Monday, January 9, 2023 at 9:45…
Why TG Therapeutics Stock Was a Solid Winner This Week
The company scored a giant victory on the regulatory front....…
Stocks making the biggest moves midday: TG Therapeutics, Micron Technology, ChargePoint and more
These are the stocks posting the largest moves in midday trading....…
Analyst Ratings for TG Therapeutics
Latest Ratings for TGTX
DateFirmActionFromTo Jan 2022HC Wainwright & Co.MaintainsBuy Jan 2022HC Wainwright & Co.MaintainsBuy Dec 2021Evercore ISI GroupMaintainsOutperform…
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PALI, KALA, FSTX, NUWE, and TGTX. To…
TG Therapeutics stock price target raised to $23 from $17 at B. Riley
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets
Wednesday, the FDA approved TG Therapeutics Inc's (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS).
Latest Ratings for…
TG Therapeutics Shares Extend Gains Following FDA Approval of Briumvi
TG Therapeutics Shares Extend Gains Following FDA Approval of Briumvi...…
TG Therapeutics at 10-month high amid plans for new multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
The FDA approves TG Therapeutics (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch…
Thinking about buying stock in Quotient, TAL Education, Core Scientific, TG Therapeutics, or Rivian Automotive?
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, TAL, CORZ, TGTX, and RIVN. To…
Form 8-K TG THERAPEUTICS, INC. For: Dec 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
TG Therapeutics Up 29% on FDA Approval of MS Drug Briumvi
TG Therapeutics Up 29% on FDA Approval of MS Drug Briumvi...…
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can…
FDA Approves TG Therapeutics Inc.s MS Drug Briumvi
FDA Approves TG Therapeutics Inc.'s MS Drug Briumvi...…
TG Therapeutics spikes as FDA approves multiple sclerosis therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…